ArticleCurrent oncology (Toronto, Ont.)2025

First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.

Tobias Peres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.